Naloxone Hydrochloride Aurum Pharmaceuticals (Naloxone Hydrochloride)

Naloxone works by competitively binding to μ‑opioid receptors in the central nervous system without activating them. This displaces opioid agonists that are causing respiratory depression and sedation, thereby blocking their effects and allowing normal respiratory drive and consciousness to return within minutes after administration.

The exact dose of Naloxone is determined by the prescribing clinician based on the patient’s condition, the route of administration, and the severity of opioid toxicity. Common practice involves an initial dose of 0.4 mg to 2 mg given intravenously, intramuscularly, or subcutaneously, with additional doses as needed, but the prescriber sets the final regimen.

Safety data for Naloxone in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider before use.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Naloxone is the most widely used opioid antagonist because of its rapid onset, short duration of action, and established safety profile. Compared with alternatives such as nalmefene or naltrexone, Naloxone acts more quickly and is preferred for emergency reversal, whereas the others have longer half‑lives and are used for maintenance therapy in opioid dependence.

Naloxone should be stored at 2‑8 °C (refrigerated), protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, allow the product to reach room temperature if refrigerated, and inspect for particulate matter or discoloration. Follow standard aseptic techniques when preparing for injection.

Naloxone is administered by intramuscular, intravenous, or subcutaneous injection. The route is chosen based on the clinical situation and available access. In emergency settings, intramuscular injection is often used for rapid delivery, while intravenous administration provides the fastest onset when venous access is available.

Serious risks include the potential for acute opioid withdrawal, which can cause severe agitation, hypertension, tachycardia, and in rare cases, seizures or cardiac arrhythmias. Patients with underlying heart disease may be particularly vulnerable, so continuous monitoring of cardiovascular status after administration is essential.

Naloxone is contraindicated in individuals with a known hypersensitivity to naloxone or any of its excipients. It should also be used with caution in patients with severe cardiovascular disease, uncontrolled hypertension, or a history of seizures, as rapid reversal of opioid effects can precipitate adverse cardiovascular or neurologic events.